Advanced

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Warfvinge, Rebecca LU ; Geironson Ulfsson, Linda LU ; Sommarin, Mikael N E LU ; Lang, Stefan LU ; Karlsson, Christine LU ; Roschupkina, Teona LU ; Stenke, Leif; Stentoft, Jesper; Olsson-Strömberg, Ulla and Hjorth-Hansen, Henrik, et al. (2017) In Blood 129(17). p.2384-2394
Abstract

Understanding leukemia heterogeneity is critical for the development of curative treatments as the failure to eliminate therapy-persistent leukemic stem cells (LSCs) may result in disease relapse. Here we have combined high-throughput immunophenotypic screens with large-scale single-cell gene expression analysis to define the heterogeneity within the LSC-population in chronic phase chronic myeloid leukemia (CML) patients at diagnosis and following conventional tyrosine kinase inhibitor (TKI) treatment. Our results reveal substantial heterogeneity within the putative LSC population in CML at diagnosis and demonstrate differences in response to subsequent TKI-treatment between distinct subpopulations. Importantly, LSC subpopulations with... (More)

Understanding leukemia heterogeneity is critical for the development of curative treatments as the failure to eliminate therapy-persistent leukemic stem cells (LSCs) may result in disease relapse. Here we have combined high-throughput immunophenotypic screens with large-scale single-cell gene expression analysis to define the heterogeneity within the LSC-population in chronic phase chronic myeloid leukemia (CML) patients at diagnosis and following conventional tyrosine kinase inhibitor (TKI) treatment. Our results reveal substantial heterogeneity within the putative LSC population in CML at diagnosis and demonstrate differences in response to subsequent TKI-treatment between distinct subpopulations. Importantly, LSC subpopulations with myeloid and proliferative molecular signatures are proportionally reduced at a higher extent in response to TKI-therapy compared to subfractions displaying primitive and quiescent signatures. Additionally, cell surface expression of the CML stem cell markers CD25, CD26, and IL1RAP is high on all subpopulations at diagnosis, but downregulated and unevenly distributed across subpopulations in response to TKI-treatment. The most TKI-insensitive cells of the LSC-compartment can be captured within the CD45RA- fraction and further defined as positive for CD26 in combination with an aberrant lack of cKIT expression. Together, our results expose a considerable heterogeneity of the CML stem cell population and propose a Lin(-)CD34(+)CD38(-/low)CD45RA(-)cKIT(-)CD26(+) population as potential therapeutic target for improved therapy response.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood
volume
129
issue
17
pages
2384 - 2394
publisher
American Society of Hematology
external identifiers
  • scopus:85018906331
  • wos:000400243100012
ISSN
1528-0020
DOI
10.1182/blood-2016-07-728873
language
English
LU publication?
yes
id
8aee8135-26d1-4d3d-a9ea-9ff6e32a7d85
date added to LUP
2017-02-17 16:43:36
date last changed
2018-10-03 10:15:35
@article{8aee8135-26d1-4d3d-a9ea-9ff6e32a7d85,
  abstract     = {<p>Understanding leukemia heterogeneity is critical for the development of curative treatments as the failure to eliminate therapy-persistent leukemic stem cells (LSCs) may result in disease relapse. Here we have combined high-throughput immunophenotypic screens with large-scale single-cell gene expression analysis to define the heterogeneity within the LSC-population in chronic phase chronic myeloid leukemia (CML) patients at diagnosis and following conventional tyrosine kinase inhibitor (TKI) treatment. Our results reveal substantial heterogeneity within the putative LSC population in CML at diagnosis and demonstrate differences in response to subsequent TKI-treatment between distinct subpopulations. Importantly, LSC subpopulations with myeloid and proliferative molecular signatures are proportionally reduced at a higher extent in response to TKI-therapy compared to subfractions displaying primitive and quiescent signatures. Additionally, cell surface expression of the CML stem cell markers CD25, CD26, and IL1RAP is high on all subpopulations at diagnosis, but downregulated and unevenly distributed across subpopulations in response to TKI-treatment. The most TKI-insensitive cells of the LSC-compartment can be captured within the CD45RA- fraction and further defined as positive for CD26 in combination with an aberrant lack of cKIT expression. Together, our results expose a considerable heterogeneity of the CML stem cell population and propose a Lin(-)CD34(+)CD38(-/low)CD45RA(-)cKIT(-)CD26(+) population as potential therapeutic target for improved therapy response.</p>},
  author       = {Warfvinge, Rebecca and Geironson Ulfsson, Linda and Sommarin, Mikael N E and Lang, Stefan and Karlsson, Christine and Roschupkina, Teona and Stenke, Leif and Stentoft, Jesper and Olsson-Strömberg, Ulla and Hjorth-Hansen, Henrik and Mustjoki, Satu and Soneji, Shamit and Richter, Johan and Karlsson, Göran},
  issn         = {1528-0020},
  language     = {eng},
  number       = {17},
  pages        = {2384--2394},
  publisher    = {American Society of Hematology},
  series       = {Blood},
  title        = {Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML},
  url          = {http://dx.doi.org/10.1182/blood-2016-07-728873},
  volume       = {129},
  year         = {2017},
}